CRISPR for Covid Testing and FDA EUAs

05/17/20 • 20 min

As calls for better, faster, cheaper, portable testing for COVID-19 disease are heard around the world -- given the important role of test-trace-isolate in re-opening the economy! -- the FDA recently issued an Emergency Use Authorization (EUA) for a CRISPR-based diagnostic.

It's the first authorized use of CRISPR technology for an infectious disease test. So we discuss this topic in this week's episode of 16 Minutes -- our show where we cover the news headlines, tease apart what's hype/what's real from our vantage point in tech, and share where we are on the overall arc of various trends -- covering:

where are we with testing for COVID overall given the taxonomy of what's already here and what's coming;
where are we with CRISPR technology, given that this is the one of the first times it's being used for diagnostics vs. therapeutics (and that clinical trials are only coming of age there now;
how does this work, and how does this type of CRISPR compare to the PCR approach for testing; and
how do EUAs and more play out given past policy debates and discussions of CRISPR and gene editing

...with a16z general partner Jorge Conde and bio deal team partner Andy Tran, in conversation with Sonal Chokshi.

On 16 Minutes, we also offer frameworks for thinking about the topics covered, so we also discuss: the tradeoffs between specificity and sensitivity when it comes to testing, especially when there's a big difference in false positives in testing for the disease vs. testing for antibodies; the tradeoffs between decentralized vs. centralized testing (getting the sample to the test or getting the test to the sample), especially given the potential for pregnancy-kit like tests here; and the tradeoffs between specific, scalable, and sensible testing ...Is it possible to have it all when it comes to CRISPR??

where are we with testing for COVID overall given the taxonomy of what's already here and what's coming;
where are we with CRISPR technology, given that this is the one of the first times it's being used for diagnostics vs. therapeutics (and that clinical trials are only coming of age there now;
how does this work, and how does this type of CRISPR compare to the PCR approach for testing; and
how do EUAs and more play out given past policy debates and discussions of CRISPR and gene editing

...with a16z general partner Jorge Conde and bio deal team partner Andy Tran, in conversation with Sonal Chokshi.

Previous Episode

The Case of Zoom and Scaling Cloud Security

Zoom has not only experienced unprecedented, rapid growth (from 10M to 200M daily active users) due to the coronavirus pandemic and shelter-in-place -- but is also seeing a shift in use cases from primarily enterprise to more consumer as well. At the same time, there have been several security issues and concerns around Zoom, including "zoombombing" porn; home-grown encryption; and key-management systems, servers, and engineers in China.

The company had to correct and clarify the record as a result, but what does it mean to have enterprise-grade security How worried should we be (and who should worry) given that everyone from cycling classes and children's classes are now all online, many on Zoom or on related remote communication tools and applications? Especially now that healthcare providers (thanks to the U.S. Department of Health and Human Services Office of Civic Rights loosening up its enforcement of HIPAA regulations and related rules) are also serving patients "wherever they are during this national public health emergency”...

What's hype/what's real in the headlines here? In this episode of 16 Minutes, a16z general partner David Ulevitch (former SVP/GM at Cisco), and operating partner for security Joel de la Garza (former CSO of Box) break it all down in 16+ minutes with Sonal Chokshi. What does it all mean for related tech trends in bottom-up SaaS -- from user onboarding and the flip side of "earning the right to be complicated" to pricing & packaging -- as well as for open source; and cloud security, particularly when it comes to video?

Next Episode

The Security and Privacy of Contact Tracing

1 Recommendations

While governments, policymakers, and employers around the world are all figuring out how to reopen the economy, contact tracing -- which includes identifying and warning contacts of exposure in order to stop chains of transmission -- is a key strategy for preventing further spread of a disease like COVID-19.

But approaches vary from manual to automated. And different regions have different frameworks, whether combined with GPS (location data) and CCTV as in South Korea -- or mainly Bluetooth-based, as in Singapore and elsewhere. The players and apps also vary in whether they're from corporations, grassroots/citizen efforts; employer-facing or for widespread public-health surveillance; or even just open vs. closed, decentralized vs. centralized, and so on.

So we break it all down in this week's episode of 16 Minutes on the News with Joel de la Garza, in conversation with Sonal Chokshi, given headlines around Apple and Google’s approach, called "privacy-safe contact tracing". What ARE the security and privacy concerns here? Yet technology is not the biggest part of this discussion; it’s also about rights, cultures, and values... and the bigger questions around what happens when people are "transformed into cellphone signals".